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Abstract.
Background: Hope for future treatments to prevent or slow down dementia motivates researchers to strive for ever-earlier
diagnoses of Alzheimer’s disease (AD) based on biomarkers, even before symptoms occur. But is a biomarker-based early
diagnosis desirable in clinical practice?
Objective: This study explores the ethical considerations that shape current clinical practice regarding early AD diagnostics
and the use of biomarkers.
Methods: In this qualitative study, Dutch physicians were interviewed. Topics included physicians’ views concerning early
AD diagnosis in persons with no or mild cognitive impairment, physicians’ considerations regarding current and expected
future practices of early AD diagnosis, the use of biomarkers, and the use of the concepts preclinical and prodromal AD. We
analyzed the transcripts using directed content analysis.
Results: 15 general practitioners, neurologists, and geriatricians in the Netherlands were interviewed. Most of them interpreted
an early AD diagnosis with an early diagnosis of dementia. We identified six clusters of considerations sometimes in favor but
most often against pursuing an early AD diagnosis in people with no or mild cognitive impairment that influence physicians’
diagnostic decision-making: preferences and characteristics of persons, test characteristics, impact on care, type of setting,
disease concepts, and issues on a societal level.
Conclusion: The discussion concerning an early AD diagnosis based on biomarkers which is widely held in the scientific
field, has not entered clinical practice structurally. A biomarker-based early diagnosis does not fit within Dutch physicians’
views on what good care for people with no, subjective, or mild cognitive impairment should entail.
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INTRODUCTION
In the hope for future treatments to prevent or slow
down dementia, there is a strong movement toward an
ever-earlier diagnosis of Alzheimer’s disease (AD),
even before symptoms occur. But should we pursue
such an early diagnosis in clinical practice, and is this
ethically desirable?
ISSN 1387-2877/21/$35.00 © 2021 – The authors. Published by IOS Press. This is an Open Access article distributed under
the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0).
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The focus on an early diagnosis of AD caused a
shift in the definition of the disease in the research
setting [1]. AD has long been defined by clinical sy-
mptoms of cognitive impairment and functional
decline, but now researchers increasingly base the
diagnosis in a research setting on biological mea-
sures (biomarkers) [1]. It has become possible to
detect these biomarkers, e.g. amyloid- and tau, in
cerebrospinal fluid or on neuroimaging with a pos-
itron emission tomography (PET) scan, that are pre-
sumed to reflect brain changes eventually leading to
dementia, in persons with no or only mild cognitive
impairment. This has led to a reconceptualization
of AD, and newly proposed concepts of ‘preclini-
cal’ and ‘prodromal’ AD for those who test positive
of AD biomarkers but have no dementia [2]. While
currently mainly used in research, these biomark-
ers and the concepts of preclinical and prodromal
AD are moving into clinical practice [3–5]. Specific
efforts are being made to set up action plans—a strate-
gic research agenda or roadmap—to accelerate the
adoption of these AD biomarkers in clinical practice
[6].
This transition of early AD diagnostics into clinical
practice raises both questions of (scientific) validity
as of (ethical) desirability. Most research looks at the
former, mainly focused on diagnostic accuracy: What
is the added diagnostic value of specific biomarkers
[5, 7]? However, much less attention is paid to the
latter questions: Is this shift to an ever earlier diagno-
sis of AD desirable and worth pursuing? What is the
value of knowing such a diagnosis, what are the harms
and benefits? These types of questions are crucial
to ask and answer before embedding AD biomarker
testing in clinical practice.
While questions concerning desirability of early
AD diagnostics in clinical practice have been add-
ressed by scholars from ethics and social science
[8–10], little empirical research is done to inform
this ethical debate. The empirical research that is per-
formed up until now focuses mostly on those rec-
eiving biomarker testing (patients); not on those
providing biomarker testing (medical practitioners)
[11]. Knowledge of current clinical practices regard-
ing early AD diagnostics and the use of AD biomark-
ers in persons with no or mild cognitive impairment,
as well as of the scientific and ethical reasoning
behind this practice as seen from the point of view of
medical practitioners, is scarce [8]. In order to inves-
tigate the desirability of early AD diagnostics and the
use of AD biomarkers, it is essential to first establish
how it would fit within current clinical practice and
to take the perspectives and arguments from those
involved in that practice into account [12].
Therefore, this study aimed to explore the consid-
erations that shape current clinical practice regarding
early AD diagnostics and the use of AD biomarkers.
We focused on physicians’ views concerning early
AD diagnosis in persons with no or mild cognitive im-
pairment, physician’s considerations regarding cur-
rent and future practices of early AD diagnosis, the
use of biomarkers, and the use of the concepts pre-
clinical and prodromal AD.
METHODS
This qualitative interview study is reported in
accordance with the consolidated criteria for report-
ing qualitative research (COREQ) [13]. Contributing
researchers are trained and experienced in qualita-
tive research methodology, medical ethics, health and
neuroscience, or medicine.
Study setting and population
Between July 2017 and February 2018, we rec-
ruited physicians (general practitioners, geriatricians,
and neurologists) in the Netherlands who routi-
nely perform diagnostics in patients with memory
complaints or have reasonable experience with diag-
nostics in dementia. In the Netherlands, dementia can
be diagnosed and consequently followed-up either by
a general practitioner or a medical specialist accord-
ing to current guidelines. Additionally, patients need
a referral from a GP to visit a specialized memory
clinic. Relevant national guidelines are the guideline
of general practitioners [NHG standaard Dementie],
2012; the multidisciplinary guideline [Dementie],
2014; and its addendum [Addendum Mild Cognitive
Impairment], 2017. We invited physicians by email
with information about the goal and content of the
interview and overarching research project, and the
question to participate in the interview study.
To do justice to the variety of clinical practice
and to ensure a wide range of perspectives, we used
purposive sampling for the selection of the study po-
pulation [14]. Characteristics taken into account for
this sample were: physician’s specialism (general
practitioners, geriatricians, neurologists); gender; ye-
ars of work experience (ample diversity in experi-
ence); location (scattered around the Netherlands);
and setting (general practice, academic and commu-
nity hospitals).
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Table 1
Vignettes (what would you do and why?)
Specialism Vignette
of interviewee
General A 74-year-old man, with only a gallbladder operation 20 years ago
practitioner in his medical history, comes to you with memory complaints.
He is worried about this.
Neurologist A 74-year-old man, with only a gallbladder operation 20 years ago in his medical
history, has visited his general practitioner because of memory complaints.
At the GP the MMSE was 29/30 and the clock drawing test was performed well.
It has been decided to refer the man to you as a neurologist
because of the memory complaints.
Geriatrician A 74-year-old man, with only a gallbladder operation 20 years ago
in his medical history, has visited his general practitioner because
of memory complaints. At the GP the MMSE was 29/30 and the clock
drawing test was performed well. It has been decided to refer
the man to you as a geriatrician because of the memory complaints.
We ended enrolment of participants when theoret-
ical saturation was reached for answering the main
research question and no new concepts emerged [15].
When no new concepts emerged, we performed one
additional interview to confirm saturation.
This qualitative interview study was deemed
exempt from ethics approval by the research ethics
committee of the Erasmus Medical Center (proto-
col number: MEC-2017-272). Oral informed consent
was obtained from all physicians before the inter-
view commenced. All was in accordance with Dutch
legislation for medical research with humans.
Data collection
Two researchers (KT and/or MS), trained and
experienced in interviewing techniques, conducted
semi-structured interviews with physicians in a pri-
vate setting at their office or at home. Interviews
lasted approximately 1 hour. To elucidate the consid-
erations of physicians regarding early AD diagnosis,
the interview guide included three parts: 1) Practice
of diagnostics; 2) Terminology; 3) Expectations for
the future (Supplementary Table 1). Part 1 of the
interview commenced with a vignette, adapted per
specialism to start the discussion (Table 1). These
vignettes included a standardized case description of
an older person with memory complaints for which
the physician was asked what he/she would do and
why. Part 2 included a discussion about used and pre-
ferred terminology (e.g., preclinical AD, prodromal
AD, MCI). Part 3 included reflections on the future
of AD diagnostics (including hopes, doom scenarios,
and reality). The interviews were audio taped and
transcribed verbatim.
Analysis
We analyzed the interviews using directed con-
tent analysis [16]. The initial coding tree was based
on the interview guide and included: 1) Response to
vignette; 2) Considerations for diagnostic choices; 3)
Terminology; 4) Expectations, hopes, and concerns
for the future. The subcoding tree for the considera-
tions for diagnostic choices in this directed approach
was based on previous research of the authors, includ-
ing a systematic literature review of ethical arguments
in favor or against AD biomarker testing in people
with no or mild cognitive impairment [17]. To do
justice to new emerging concepts, open coding was
used when the considerations did not match the initial
subcoding tree.
In the first phase of coding and analysis, two
researchers (KT and MS) both independently coded
two interviews to limit the risk of bias and subjectivity
in the analysis. We adapted and elaborated the initial
coding tree based on data from these two interviews.
Disagreements were settled by consensus. This cod-
ing tree was discussed with the other researchers (MP,
ER, and MHS).
In the second phase, the remaining interviews were
coded by MS and subsequently reviewed by KT. Dis-
agreements were settled by consensus. This coding
was based on the initial coding tree that was adapted
and elaborated based on new concepts emerging from
the data.
In the third phase, axial coding of the data was
performed to identify clusters of considerations in
the interviews. KT performed this coding, and it was
reviewed by MS and discussed with MHS and MP.
Disagreements were settled by consensus.
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Coding and analysis continued until no new codes,
concepts, or patterns could be identified from the
data. The process of analysis was supported by QSR




Between July 2017 and February 2018, we
approached 21 potential participants. Four physicians
did not respond to our request and two declined par-
ticipation because of time constraints. Eventually, 15
physicians participated in this interview study. We
interviewed five general practitioners (GPs), six geri-
atricians, and four neurologists. Six of them were
female and nine were male. Of the medical special-
ists, four currently worked in an academic hospital
and six in a community hospital. Their work experi-
ence as a physician ranged from 8 to 35 years; their
experience in the field of dementia ranged from 5 to
35 years. They were all experienced in dementia diag-
nostics, but variation within the group was present
concerning depth and frequency of these practices.
Due to the large risk of identification of interviewees
in a small country as the Netherlands, no table illus-
trating the characteristics per individual was added.
Use of AD terminology
Analysis of the interviews shows that use of ter-
minology related to AD is very diverse among the
participants and inconsistent, even within a person.
Participants often use analogies with other diseases
(e.g., diabetes, cardiovascular diseases, or cancer)
to explain the disease concepts they prefer to use.
Preferred terminology and considerations concern-
ing desirability are related to each other, e.g., the used
analogy explained the choice for a specific care plan.
Table 2 contains illustrative quotes concerning AD
terminology.
First, interviewees differ in their definition of AD.
For example, one interviewee mentions to have found
evidence for AD in a cognitively healthy individual;
he uses a biological definition of AD. Others said
biomarkers had no additional value, because an AD
diagnosis can only be based on clinical symptoms of
dementia; they use a clinical definition of AD.
Second, almost none of the interviewed physicians
associate ‘early AD diagnosis’ with making a diag-
nosis before symptoms arise. Most of them associate
the term ‘early AD diagnosis’ with early signaling
of dementia or other cognitive impairment: the early
detection of problematic functional signs in daily liv-
ing that indicate something is wrong in daily life (e.g.,
forgetting appointments, unkempt appearance).
Third, few of the interviewed physicians know the
difference between preclinical and prodromal AD.
Two interviewees acknowledge using these terms, but
none of the physicians use the terms in their com-
munication with patients. After explanations of con-
cepts, most of the participants would not deem these
terminologies fit to use in clinical practice (neither
with colleagues nor with patients), mostly because it
would cause misunderstanding and worries about the
future. Physicians make a clear distinction between
the usefulness of these terms for clinical practice and
in research. They do recognize the usefulness of the
terms in the research setting.
Clusters of considerations concerning early AD
diagnosis
Directed content analysis revealed six clusters of
considerations concerning the desirability of early
AD diagnosis in persons with no or mild cogni-
tive impairment that influence physicians’ diagnostic
decision-making. They relate to person (seeking med-
ical help), test, care, setting, disease, and society. An
overview of these clusters (axial coding tree) is shown
in Table 3. Table 4 contains illustrative quotes per
cluster.
Cluster 1: Person-related considerations
Many of the considerations concerning the desir-
ability of an early AD diagnosis are related to the
person seeking medical help (person-related consid-
erations). These considerations can be categorized
into preferences of the person and characteristics of
the person.
First reactions to the vignettes are mostly related
to the existence of a request for help from the per-
son (or family members). Interviewees’ first action
would be to ask the person what their request for help
would be. Why are they here, what are they worried
about, and what do they want from their physician?
All physicians have a strong emphasis on address-
ing and respecting the wishes of the person. Wishes
explicitly mentioned by interviewed physicians influ-
encing their decision for diagnostic work-up include
a person’s (lack of) desire to know, and desire for
reassurance.
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Table 2
Examples of use of AD related terminology
Terminology Quote
Definition of AD
Alzheimer – dementia “Dementia is . . . Alzheimer’s Disease is. . . . dementia is in any case a clinical condition,
‘so you’ll have to have symptoms for that. Alzheimer’s is of course a disease, so in that sense
you could diagnose Alzheimer’s before someone has a dementia and notices that he is going to get it.
I don’t see those people, luckily I would almost say, because it seems like a huge drama to tell people
two years before they get dementia that they have Alzheimer’s Disease.”
(geriatrician, ID-No. 34)
Alzheimer – dementia “And it is true that I, that if you really diagnose dementia, then you first diagnose dementia and
then you can think: ‘Yes, I think this is typically more of an Alzheimer’s pattern or I find this more
of a typical vascular pattern.’ But I think if you cut those heads open then it’s all
a bit of this and a bit of that. So I actually mainly use the diagnosis dementia and not
just Alzheimer’s Disease.”
(general practitioner, ID-No. 14)
Analogies “No, because then you call it a so-called non-dementia Alzheimer’s Disease. So you do have
Alzheimer’s Disease, but you are not demented. That is quite interesting... You are sero positive
but you do not yet have HIV.”
(geriatrician, ID-No. 32)
Analogies “We’ve got our hands full with treating people with hypertension and diabetes, we are not at
all waiting for ‘pre- conditions’, and that also applies to dementia as far as I am concerned.”
(geriatrician, ID-No. 33)
Early signalling “So is it that when he meets someone on the street that he doesn’t come up with that name,
or does he forget the name of his children? That makes quite a difference. And do other things
go wrong? So things go wrong not only in cognitive but also in executive functions?... Uhm, and based
on that I make an assessment as to whether I am actually thinking of a real memory problem.”
(general practitioner, ID-No. 12)
Preclinical and “[I do not use preclinical and prodromal] . . . no. If it is a diagnosis it must be a hard one and
prodromal AD then there must be consequences to it.”
(neurologist, ID-No. 24)
Other terminology “Then I have to pay close attention to what I write down, because if I know of that person that Alzheimer’s
is a kind of specter and I [write that down], well then he will have a depression in no time.
And if I choose terms like: ‘your memory rattles so you don’t remember things quite well and that makes
you anxious and restless,’ if that is noted for that person and that helps, then I write that down.”
(general practitioner, ID-No. 13)
Table 3
Clusters of considerations overview (axial coding tree)
PERSON-related TEST-related
Characteristics Preferences / whishes Test-specific issues
Presence and severity of symptoms Request for help Risk and burden of the test
Presence and severity of signaling issues Reassurance (of family) Diagnostic accuracy
Age Patient wants / doesn’t want to know Costs of the test
Level of education
Personal background
CARE – related SETTING – related
Exclude other possible causes Research
Relevance of specifying dementia subtype Population screening
Provide (or lack of) preventive treatment General practice
Provide (or lack of) other health benefits Hospital – specialist
Increased planning possibilities Official guidelines
Offer practical guidance and support Local protocol or individual physician habits
Provide comfort and enable acceptance
DISEASE – related SOCIETY - related
Difference disease and normal ageing Costs of care
Effect of label/diagnosis Medicalization/medical interfering
Specific terminology Influence of media and other powers
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Table 4
Examples of considerations
(Cluster of) Consideration Quote
Person-related considerations
Characteristics - age “If you see someone aged 85 and you are going to do that, well, what do you want to achieve
with that? Then it could well be that Alzheimer’s abnormalities are found in the CSF,
while it is not said at all that that patient suffers from Alzheimer’s Disease, because
that is something else.”
(neurologist, ID-No. 22)
Characteristics and preferences “And with aging... I think... it’s linked to age too. Cognitive decline and Alzheimer’s, that’s just
an age disease you could almost say. And those older people are waiting much less for all
kinds of diagnostics than we do, I would almost say. Look, when you are 50, 60 and you
are very anxious because you have seen a lot of dementia in your surroundings or you
are very afraid that you will get it and you absolutely do not want that, then you may want
to have those biomarkers checked.”
(geriatrician, ID-No. 31)
Preferences – patient wants to “... On the other hand, I am also very much in favor of it . . . I mean, I won’t be someone
who says you can’t, because I don’t support that, not that. If people have good arguments
and say that it feels good to them, then I would like to do that, then I think that’s fine.”
(general practitioner, ID-No. 14)
Preferences – request for help “You can ask people that: ‘Oh what makes you come here now, what do you expect from me?’
I can think of all sorts of things, but before I get started right away: ‘I [...] am just curious
what you would like me to do. And when will you leave satisfied?’ [...] If people come
themselves, it is rare for dementia to occur. When people come themselves,
it is usually fear of dementia.”
(general practitioner, ID-No. 13)
Test-related considerations
Diagnostic accuracy – certainty “The technical assessment is actually such that it is not necessary, not strictly necessary.
And in that respect, there is a kind of ambiguity, even within myself. That on the one hand
I think it is not really necessary, it will not produce anything, sometimes I actually said that
in advance: ‘I do not expect any miracles and you must not either, but we do it just to be sure’.. ”
(neurologist, ID-No. 21)
Risk and burden of test “And I think that this kind of diagnostic work-up [conversation at home with MMSE] is much
more pleasant for that lady and for that family, than hoisting someone like that in a bus to the
hospital and pulling them through a scan and doing an amyloid measurement and an LP
that does not add much more”
(geriatrician, ID-No. 33)
Costs of the test “Well that means if you can do it with simpler diagnostics: a CT instead of an MRI,
no PET, no lumbar puncture, just wait and see, let time do its work, then that . . .
will cost less without harming your patient.”
(geriatrician, ID-No. 34)
Care-related considerations
Lack of therapy “My expectation is actually that we let those biomarkers fade into the background,
which is the opposite of what a geriatrician probably thinks. Because it makes no sense at all
in this aging society to do a lot of early diagnostics, because we don’t have any medication yet
either to slow it down. Those plasters don’t help at all.. There is nothing else. So when there
is treatment, it makes sense to do early diagnostics, but at the moment it has no added value at all.”
(general practitioner, ID-No. 12)
Lack of benefit “So then I think, yes then you can impose that on someone and say: ‘Look, you have a dementia
label.’ But it must have a function, or it must be able to contribute to a better happiness,
so to speak.”
(general practitioner, ID-No. 14)
Provide other benefits – “Because now we also do not have a treatment and yet we make the diagnosis.
offer support Because I think making the diagnosis is of added value. And that added value is not so much
in prescribing someone pills or sticking plasters . . . . But it can help to get an indication
to arrange better healthcare.”
(geriatrician, ID-No. 33)
General practice “From the world of dementia professionals, early diagnostics is a bit sacred, isn’t it?
There must be early diagnostics.... but the GPs are also the group that sees that not much works.
So they have something like yes I can send a person to the hospital, but what does that
specialist do? Yes, a battery of tests and they can’t do anything else... So that does not motivate
a general practitioner.”
(geriatrician, ID-No. 31)
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Table 4
Continued
(Cluster of) Consideration Quote
Setting-related considerations
Research purpose “Or if someone says I want to know because I am considering to take part in a trial with
some new medicine in [tertiary memory clinic]. Yes, I also think that is a valid argument.”
(neurologist, ID-No. 22)
Official guideline “I am not entirely up-to-date with the latest state of science in this area. So I follow the guideline,
which is now just three years or a little older.”
(geriatrician, ID-No. 34)
Disease-related considerations
Disease – normal ageing “In my opinion, we are talking about an aging condition. So we make... we have developed a lot
as doctors that make people get older and I think Alzheimer’s really is an aging condition that of
course involves all kinds of things in our society, but ultimately because people get old enough.
That’s just like those people with a prostate [cancer], if you grow old enough then you die with
Alzheimer’s.[ . . . ] Yes, I think that indeed makes my opinion different from someone
who sees it as a disease [...] yes I mean Alzheimer’s is a part predisposition,
a part environment, part aging, there are a lot of things.”
(general practitioner, ID-No. 13)
Effect of label – diagnosis “It may help to make an early diagnosis [ . . . ] but then how early do you want to know that
you have Alzheimer’s Disease? Don’t you give more disease burden to a patient who
is not yet ill at all, which I have experienced very strongly with this patient.”
(general practitioner, ID-No. 12)
Society-related considerations
Medicalization “Because it is apparently not yet an issue for the patient. And that has something to do
with when you notice early if someone has Alzheimer’s disease, people are sick for a longer
time. [ . . . ] I do not use them and as far as I know there are no significant markers.
And I am a general practitioner, so I think you should let people be sick
for as short a time as possible.”
(general practitioner, ID-No. 15)
Medicalization “I think that is a flaw of this modern age, the misconception that knowledge
makes you happier.”
(neurologist, ID-No. 24)
Influence of media “And you see the same thing with people with diabetes... and a driver behind that to
and other powers help these kinds of entities into the world . . . are often, certainly in the world of hypertension
and diabetes, driven by pharmaceutical companies that want to expand the market and not
at all by doctors who are waiting for: ‘O yes now we can do something’ ”
(geriatrician, ID-No. 33)
Influence of media “Well, I find that is very much inclined towards... because that, of course, also comes
and other powers from somewhere, then I didn’t force it upon him or her as an agency or as a professional,
but then others forced it upon him or her.”
(neurologist, ID-No. 21)
Additionally, the interviewees all want to find out
the presence and severity of the symptoms (e.g.,
memory complaints, limitations in daily functions)
and explore other signaling issues (e.g., unkempt
appearance, spoiled food in refrigerator). Even when
the interviewer emphasizes that no symptoms or other
signals are presented in the vignette, they keep cir-
cling back to situations in which individuals show
symptoms and give arguments for their decision mak-
ing in a scenario where a person shows symptoms. A
higher age is a characteristic that is mentioned reg-
ularly as a strong indicator for the physician not to
consider and pursue an early AD diagnosis by use
of biomarkers, because of two reasons: symptoms
are considered a part of normal aging, and there is
a strong likelihood for multifactorial causes of symp-
toms. Other person-characteristics mentioned by the
interviewees as influencing their decision include
the level of education and personal background of
the person seeking medical help.
Cluster 2: Test-related considerations
Many of the interviewees think that a biomarker
does not have additional value in the diagnostic pro-
cess, especially in older age. The (lack of) diagnostic
accuracy (including validity and test-performance)
is an important test-related consideration influencing
their decision making. Other test-related considera-
tions include arguments on the costs of such tests, the
risk and burden of these tests, and test-specific issues.
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There is a large variability in knowledge among
physicians concerning biomarkers. Additionally, they
also value this knowledge differently: Interviewees
consider different levels of test characteristics as suf-
ficient or adequate for implementation of a test in
clinical practice. For example, some refer to a spe-
cific percentage of sensitivity as enough evidence to
implement a test, while others refer to that same
specific number of that test as not enough evidence
for implementation. When discussing diagnostic or
prognostic testing for AD, most interviewees refer to
memory testing. Rarely interviewees brought up the
use of biomarkers in this context and if so, they only
referred to CSF testing for exceptional cases. Most of
them do not know details about specific neuroimaging
biomarkers like PET-scans. Genetic testing for APOE
4, which indicates an increased risk to develop AD
dementia, was also not considered.
Although costs are not mentioned as a factor in
individual decision-making or in referring a person,
costs (specifically of PET-Amyloid) are mentioned
on a societal level, especially when one considers
screening for AD in the general population as a future
scenario. Physicians also emphasize that the risks and
burdens of these biomarker tests should be taken into
consideration.
Cluster 3: Care related considerations
Some of the considerations the interviewed physi-
cians mention are specifically care-oriented: what do
we aim at by pursuing an early AD diagnosis? These
considerations all center on the care that can and
should be offered when pursuing an AD diagnosis.
Although the interview focused on those with no or
mild cognitive impairment who seek medical atten-
tion, some interviewees mention specifically that it is
crucial to specify the dementia subtype for those with
cognitive impairment, and that you can and should
use biomarkers for that purpose. While others men-
tion the opposite: specifying dementia subtypes will
have no impact on the care trajectory, therefore there
is no reason to pursue a biomarker test not even in
those with cognitive impairment.
The current lack of preventive therapies and other
health benefits is the major reason for interviewees for
not considering early AD diagnosis or AD biomark-
ers ready for implementation in clinical practice. You
don’t have anything to offer to individuals. One inter-
viewee argues the opposite: there are some preventive
measures to slow down the progression. Also, the
possibility of adapting your planning and giving guid-
ance and support can be considered a benefit of an
early diagnosis according to some interviewees. Pro-
viding comfort and enabling acceptance for both the
individual as family members is also a reason for
interviewees to pursue an early diagnosis, but only
when diagnostic certainty could be guaranteed. Large
diversity exists in whether the expectations of devel-
oping a possible treatment for AD in the future are
realistic. Some argue the finding of a treatment is
near, others wonder whether we will ever find a cure
or preventive measure.
Cluster 4: Setting-related considerations
Interviewed physicians always refer to character-
istics of a specific setting or scenario when they give
arguments for their decision. They often explicitly
distinguish between a research setting and a clinical
setting. Also, a potential population screening offer
is mentioned as a setting in which their considera-
tions would differ. Interviewees also make explicit
reference to differences in specialties. For example,
the strength of the continuous relationship between
patient and GP and repetitive contact moments in
the GP setting makes the added value of biomark-
ers redundant to some physicians. Interviewees claim
that with a proper follow up they can be equally or
even better informed than with a biomarker result.
Others refer to the (un)availability of and expertise in
specific imaging techniques in their specialty. Also,
physicians refer to current national guidelines and
local protocols when asked to elucidate their choices.
They justify their choice of action by referring and
adhering to these documents.
Cluster 5: Disease-related considerations
A fifth cluster of considerations is related to dis-
ease-concepts, that is, interviewees’ (implicit) norms
on what should be considered a disease and what
is part of normal aging. Many times, when physicians
exemplify their reasons for not applying (biomarkers
for) an early AD diagnosis, they refer to the fact that
they consider the mild symptoms to be normal aging,
especially in the older population. When symptoms
are ascribed to normal aging, individuals should not
be exposed to unnecessary medical scrutiny. The
desirability of biomarker testing is strongly depen-
dent on whether an interviewee frames it as testing
for a diagnostic purpose or prognostic purpose. For
example, physicians said that with AD biomarker
testing you test for a risk for developing a disease,
not for a disease in itself. Also, the possible negative
effects of a diagnosis (or label) itself is mentioned
in their argumentation for not considering an early
diagnosis desirable.
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Cluster 6: Society-related considerations
A final cluster of considerations concerns refer-
ence to society as a whole. Fear of medicalization
is mentioned by interviewed physicians as an impor-
tant factor for not pursuing an early AD diagnosis
in their patients. This argument is closely linked to
disease-concepts and the difference between disease
and normal aging. They emphasize that this shift
toward an ever earlier diagnosis stems from a ten-
dency to medicalize everything and the concern is that
medical testing would bring more harm than good for
the individual and society. Other societal considera-
tions are concerned with the costs of and access to
possible new treatments and whether or not science
should invest in finding a (preventive) treatment for
AD or rather focus on improving care and support.
Physicians also mention the influence that the media
and other powers (e.g., pharmaceutical companies)
have on both medical practitioners and patients and
how this can affect how people view the desirability
of pursuing an early AD diagnosis.
DISCUSSION
Our study shows that the arguments Dutch physi-
cians use in favor and against pursuing an early
AD diagnosis in persons with no or mild cognitive
impairment and testing AD biomarkers in clinical
practice transcend the commonly used arguments in
scientific literature. Arguments used in the litera-
ture mostly relate to validity and test performance of
these biomarkers [5–7, 19]. The interviewed physi-
cians in our study used much more diverse arguments
to explicate their normative stance toward early AD
diagnosis and biomarkers in clinical practice. They
emphasized for example the (lack of) impact of bio-
marker testing and early AD diagnosis on patient
care and care trajectories. These arguments were cat-
egorized as care-related arguments in the results sec-
tion and can be linked to the ethical principle of
beneficence. Physicians who were relatively skepti-
cal about a future rise of biomarker testing expressed
doubts on whether this would be a just use of scarce
healthcare resources. This concern can be linked
to the ethical principle of justice. Additionally, the
importance of meeting a person’s wishes—thereby
respecting his/her autonomy—was an important
reason for physicians to decide about pursuing
biomarker testing. Previous research concluded that
whether biomarker testing for early AD diagnosis is
desirable, depends on the individual context in which
testing is considered [17]. The six clusters identified
in this interview study (person, disease, test charac-
teristics, setting, care, and society related arguments)
give a more focused and detailed description of this
individual context and show the normative angle in
the argumentation of physicians concerning desir-
ability of pursuing an early AD diagnosis in clinical
practice. The variety in physicians’ considerations
shows us which values are taken into account when
aiming to incorporate AD biomarkers in clinical prac-
tice. Physician’s arguments are relevant in the debate
on the ethical desirability of AD biomarker testing
because they have moral experience with diagnosis
of and care for people with cognitive complaints.
Furthermore, if AD biomarker testing is pursued in
clinical practice, it should fit their practice in a respon-
sible way.
We designed this study in light of the rise of bio-
marker testing for early AD diagnosis in people
without dementia that is described in research [1,
6]. However, most interviewed physicians, from pri-
mary to tertiary care and with diverse specialties,
do not associate early AD diagnosis with setting a
diagnosis in people without dementia. To most inter-
viewed physicians, according to whom AD refers to
dementia, ‘early’ refers to an early stage of demen-
tia. Therefore, for them an early AD diagnosis means
early signaling of dementia and MCI: the early detec-
tion of problematic functional signs. In contrast to
what is described in some research on clinical utility
of AD biomarker testing [20], people with no objec-
tive symptoms (who are curious to know their AD
risk status) did not seem to fit within their framework
of reference. Consequently, most of the interviewees
did not pursue early diagnosis of AD in a stage before
early dementia. This observation is in line with the
two parallel definitions for AD that are currently
being applied: A definition of AD that also applies to
people with no or mild cognitive impairment based
on biomarker status [1]; and a definition of AD that
relies on clinical symptoms of dementia [21]. Our
results show how miscommunication may arise when
these definitions, meant for different settings, would
be used simultaneously in a clinical setting, i.e., some
physicians might diagnose a patient with ‘preclinical
AD’, while others would not diagnose the same per-
son at all, and consider them healthy. Moreover, there
are strong reasons to indeed limit the biological def-
inition of AD to be only used in the research setting
because of the potential negative consequences of an
AD diagnosis for people with subjective or mild cog-
nitive impairment in absence of an effective treatment
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[2, 22]. Therefore, and in line with previous recom-
mendations by Alzheimer Europe [23], the results
from this interview study do not support the use of
proposed new disease categories prodromal AD or
preclinical AD in clinical practice.
Our results thus show that the discussion concern-
ing a diagnosis of AD based on biomarkers which
is widely held in the scientific field, has not entered
Dutch clinical practice structurally. In the research-
community, there is a tendency by some scholars
to expect and promote a wider implementation of
AD biomarkers in clinical practice [6]. This ten-
dency relies on the assumption that there are a lot
of people with no or subjective cognitive impairment
who would appreciate a diagnosis before symptoms
and would visit a physician for this. In contrast,
physicians interviewed in this study are hardly ever
confronted with people with these requests. This
exposes an additional mismatch of views presented
by researchers in the scientific literature [6, 19, 24],
with views held by physicians in wider clinical prac-
tice. The considerations that shape the practice of
physicians working routine clinical care, as described
above, may broaden the perspective of physicians
working in memory clinics, who are familiar with a
relatively narrow patient population, and researchers.
Strengths of this study include data-triangulation
and the combination of experiences from clinical
practice with analysis of moral reasoning. Also, the
involvement of a multidisciplinary research team
contributed to addressing the issue of early AD diag-
nosis in clinical practice from diverse relevant angles.
A potential weakness of the study is the inability to
translate and apply the findings to other countries, as
the study only concerns the views of physicians in
the Netherlands and the practice of AD diagnostics
is to some extent country specific. Justice related con-
siderations including the costs of biomarker testing
or insurance related issues, for example, differ per
country.
CONCLUSION
The possibility to diagnose AD in people with
subjective or mild cognitive impairment based on
biomarker results in clinical practice is increasingly
presented as an ideal in scientific literature [20, 24].
This ideal seems not in line with current clinical prac-
tice in the Netherlands. More importantly, it does
not fit with views of Dutch physicians on what good
care for people with no, subjective, or mild cognitive
impairment should entail. This discrepancy between
research expectations and clinical practice needs to
be addressed by physicians, researchers, and pol-
icy makers to avoid false expectations in patients.
In dealing with this discrepancy, clinicians’ exper-
tise regarding what ‘good care’ consists of, should be
taken very seriously.
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